EDE approves MIMRYLO for rare blood disorder as UAE becomes 2nd global market

The Emirates Drug Establishment (EDE) has approved MIMRYLO (rusfertide) for adults with polycythemia vera, making the UAE the second country globally to authorise the medicine, according to Khaleej Times coverage of the approval.

The decision matters first for Dubai hematology clinics and hospital pharmacies, then for providers in Abu Dhabi and the northern emirates. Polycythemia vera is a rare chronic blood disorder in which the body produces too many red blood cells. That can thicken blood and increase the risk of clots, stroke and heart attack. For operators, the approval creates a near-term question: which eligible patients move from repeated phlebotomy-based control to a weekly injectable treatment, and who pays for it?

What EDE approved

MIMRYLO is a hepcidin mimetic. The US Food and Drug Administration (FDA), which approved the drug on 28 August 2026, describes hepcidin as a hormone that regulates iron availability for red blood cell production. By limiting available iron, rusfertide helps control erythrocytosis in adults with polycythemia vera. The FDA approval notice says the drug is intended for patients whose disease has not been adequately controlled with existing therapies.

The product is supplied as single-dose vials of lyophilised powder for reconstitution. The US prescribing information lists a recommended starting dose of 19 mg once weekly by subcutaneous injection, with dose adjustment up to 108 mg weekly. It also says complete blood count monitoring should occur every 2 to 4 weeks after initiation and during dose changes, or as clinically indicated.

“The approval reflects the Establishment's commitment to developing a regulatory model capable of keeping pace with advanced therapeutic innovation and accelerating access to such treatments through rigorous scientific assessment.” Dr Fatima Al Kaabi, Director General, Emirates Drug Establishment.

What clinics and insurers need to decide

For Dubai Health Authority (DHA)-licensed providers, the operational issue is pathway design. Hematologists will need criteria for eligibility, patient consent, injection training, reconstitution steps, lab monitoring and adverse-event capture. Department of Health Abu Dhabi (DOH)-regulated providers face the same clinical protocol work, with a sharper payer interface where Daman and Thiqa coverage decisions can affect uptake. In the northern emirates, Ministry of Health and Prevention (MOHAP)-linked facilities and private providers will need to confirm local procurement and pharmacy dispensing routes once distribution is live.

The price signal is material. Takeda has not published a UAE list price. US trade reporting put the US list price at about $4,200 per vial, equal to roughly AED 15,400 at the dirham dollar peg before UAE-specific distributor margins, VAT, provider fees or insurer discounts. UAE CFOs should treat that as an international benchmark, not a local tariff. The practical route is to request the UAE registered price from the dispensing pharmacy or distributor, then test reimbursement through the patient’s insurer before first dose.

• Eligibility: adults with polycythemia vera and erythrocytosis, subject to the approved UAE label and physician assessment.
• Administration: weekly subcutaneous dosing, with reconstitution before use.
• Monitoring: complete blood count checks every 2 to 4 weeks during initiation and dose changes.
• Payer step: prior authorisation is likely for insured patients because the drug is a rare-disease injectable with a high international price benchmark.

Why patients may ask for it

Polycythemia vera patients have often relied on phlebotomy, cytoreductive therapy and symptom control. The Takeda FDA announcement said the Phase 3 VERIFY study found 76.9% of patients achieved clinical response during weeks 20 to 32. That figure will be central to medical director review, but UAE committees should still examine local label wording, exclusion criteria, safety monitoring and whether the drug replaces or supplements current care in each patient group.

For CMOs and clinic managers, demand may arrive before reimbursement pathways are settled. Patients who read that the UAE is the second global market may ask hematologists for access this quarter. Providers should prepare a short patient-facing explanation covering indication, weekly dosing, monitoring, payer approval and alternatives. The UAE Open Healthcare Directory can help patients and operators identify licensed pharmacy providers able to support regulated dispensing once UAE supply is available.